Autolus Therapeutics plc - American Depositary Share (AUTL): Price and Financial Metrics
GET POWR RATINGS... FREE!
AUTL POWR Grades
- Growth is the dimension where AUTL ranks best; there it ranks ahead of 77.37% of US stocks.
- The strongest trend for AUTL is in Growth, which has been heading up over the past 179 days.
- AUTL ranks lowest in Momentum; there it ranks in the 4th percentile.
AUTL Stock Summary
- AUTL's price/sales ratio is 164.26; that's higher than the P/S ratio of 98.34% of US stocks.
- With a year-over-year growth in debt of -61.23%, Autolus Therapeutics plc's debt growth rate surpasses only 5.2% of about US stocks.
- Shareholder yield, a measure of how much is returned to shareholders via dividends and share repurchases, for AUTL comes in at -64.28% -- higher than that of only 6.61% of stocks in our set.
- Stocks that are quantitatively similar to AUTL, based on their financial statements, market capitalization, and price volatility, are PIRS, ARDS, XCUR, AFMD, and ZYME.
- Visit AUTL's SEC page to see the company's official filings. To visit the company's web site, go to www.autolus.com.
AUTL Valuation Summary
- AUTL's price/sales ratio is 119.9; this is 956.39% higher than that of the median Healthcare stock.
- Over the past 39 months, AUTL's price/sales ratio has gone down 437.9.
- Over the past 39 months, AUTL's price/sales ratio has gone down 437.9.
Below are key valuation metrics over time for AUTL.
| Stock | Date | P/S | P/B | P/E | EV/EBIT |
|---|---|---|---|---|---|
| AUTL | 2021-08-31 | 119.9 | 1.3 | -2.5 | -1.0 |
| AUTL | 2021-08-30 | 119.4 | 1.3 | -2.4 | -1.0 |
| AUTL | 2021-08-27 | 118.5 | 1.3 | -2.4 | -0.9 |
| AUTL | 2021-08-26 | 115.2 | 1.2 | -2.4 | -0.9 |
| AUTL | 2021-08-25 | 114.4 | 1.2 | -2.3 | -0.9 |
| AUTL | 2021-08-24 | 110.0 | 1.2 | -2.2 | -0.8 |
AUTL's Quality Factors
The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.- AUTL has a Quality Grade of F, ranking ahead of 4.94% of graded US stocks.
- AUTL's asset turnover comes in at 0.008 -- ranking 401st of 682 Pharmaceutical Products stocks.
- 500 - Internal server error
The table below shows AUTL's key quality metrics over time.
| Period | Asset Turnover | Gross Margin | ROIC |
|---|---|---|---|
| 2021-09-30 | 0.008 | 1 | -1.381 |
| 2021-06-30 | 0.009 | 1 | -1.295 |
| 2021-03-31 | 0.005 | 1 | -1.315 |
| 2020-12-31 | 0.005 | 1 | -1.295 |
| 2020-09-30 | 0.005 | 1 | -1.458 |
| 2020-06-30 | 0.004 | 1 | -1.587 |
AUTL Stock Price Chart Interactive Chart >
AUTL Price/Volume Stats
| Current price | $2.56 | 52-week high | $8.23 |
| Prev. close | $2.60 | 52-week low | $2.20 |
| Day low | $2.53 | Volume | 78,876 |
| Day high | $2.65 | Avg. volume | 332,365 |
| 50-day MA | $3.57 | Dividend yield | N/A |
| 200-day MA | $5.03 | Market Cap | 232.72M |
Autolus Therapeutics plc - American Depositary Share (AUTL) Company Bio
Autolus Therapeutics is developing a pipeline of advanced programmable T cell treatment candidates for blood and solid tumor cancers. Autolus‘ T cell therapies target the the blood cancer ALL either through CD19 (in Phase I), or through targeting CD19 and CD22 (Phase I/II). The company's CD19 candidate is claimed "next-generation" due to its fast CD19 dissociation kinetics, which allows to target many CD19+ cells very rapidly. Furthermore, the company’s CAR-T cells target CD269 and TACI to treat multiple myeloma (Phase I/II). An additional candidate undergoing Phase I safety testing targets GD2, a disialoganglioside expressed on tumours of neuroectodermal origin, to treat the rare childhood brain cancer neuroblastoma. The company is based in London, England.
Latest AUTL News From Around the Web
Below are the latest news stories about Autolus Therapeutics plc that investors may wish to consider to help them evaluate AUTL as an investment opportunity.
Autolus Therapeutics to Report Fourth Quarter and Full Year 2021 Financial Results and Host Conference Call on March 10LONDON, Feb. 21, 2022 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, today announced that it will release its fourth quarter and full year 2021 financial results and operational highlights before open of U.S. markets on Thursday, March 10, 2022. Management will host a conference call and webcast at 8:30 am ET/1:30 pm GMT to discuss the company’s financial results and provide a general |
Autolus Therapeutics plc (NASDAQ: AUTL) Stock Seems Like A Good OptionAutolus Therapeutics plc (NASDAQ:AUTL) shares, rose in value on Friday, 02/18/22, with the stock price down by -2.26% to the previous days close as strong demand from buyers drove the stock to $4.32. Actively observing the price movement in the last trading, the stock closed the session at $4.42, falling within a range of $4.32 Autolus Therapeutics plc (NASDAQ: AUTL) Stock Seems Like A Good Option Read More » |
Autolus Therapeutics (AUTL) Receives a Buy from Mizuho SecuritiesIn a report released today, Mara Goldstein from Mizuho Securities maintained a Buy rating on Autolus Therapeutics (AUTL – Research Report), with a price target of $18.00. The company's shares closed last Tuesday at $4.48. According to TipRanks.com, Goldstein is a 4-star analyst with an average return of 7.8% and a 34.9% success rate. Goldstein covers the Healthcare sector, focusing on stocks such as Neoleukin Therapeutics, CASI Pharmaceuticals, and Nektar Therapeutics. Autolus Therapeutics has an analyst consensus of Strong Buy, with a price target consensus of $14.00. |
Will Autolus Therapeutics (NASDAQ:AUTL) Spend Its Cash Wisely?Just because a business does not make any money, does not mean that the stock will go down. For example, biotech and... |
Autolus Therapeutics PLC Sponsored ADR (AUTL) Loses 22.1% in 4 Weeks, Here's Why a Trend Reversal May be Around the CornerThe heavy selling pressure might have exhausted for Autolus Therapeutics PLC Sponsored ADR (AUTL) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal. |
AUTL Price Returns
| 1-mo | -27.27% |
| 3-mo | -35.35% |
| 6-mo | -59.11% |
| 1-year | -58.64% |
| 3-year | -87.86% |
| 5-year | N/A |
| YTD | -50.67% |
| 2021 | -41.95% |
| 2020 | -32.27% |
| 2019 | -59.81% |
| 2018 | N/A |
| 2017 | N/A |
Loading social stream, please wait...